Edition:
United Kingdom

Nevro Corp (NVRO.N)

NVRO.N on New York Stock Exchange

83.70USD
18 Jun 2018
Change (% chg)

$0.10 (+0.12%)
Prev Close
$83.60
Open
$83.20
Day's High
$84.33
Day's Low
$82.78
Volume
58,326
Avg. Vol
78,842
52-wk High
$94.32
52-wk Low
$65.35

Chart for

About

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic... (more)

Overall

Beta: --
Market Cap(Mil.): $2,714.65
Shares Outstanding(Mil.): 29.44
Dividend: --
Yield (%): --

Financials

  NVRO.N Industry Sector
P/E (TTM): -- 32.19 32.75
EPS (TTM): -1.37 -- --
ROI: -10.41 13.89 14.38
ROE: -16.35 16.72 16.07

BRIEF-Nevro Reports Qtrly Loss Per Share $0.59

* REITERATES ITS EXPECTATIONS FOR WORLDWIDE REVENUE FOR 2018 TO BE IN RANGE OF $400 TO $410 MILLION

07 May 2018

BRIEF-Nevro Corp Says CEO Rami Elghandour's FY 2017 Total Compensation Was $13.2 Mln

* NEVRO CORP SAYS CEO RAMI ELGHANDOUR'S FY 2017 TOTAL COMPENSATION WAS $13.2 MLN VS $11.5 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2GEJ7Jw] Further company coverage:

06 Apr 2018

BRIEF-Nevro Qtrly Loss Per Share $0.15

* NEVRO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES 2018 OUTLOOK

22 Feb 2018

BRIEF-Nevro Receives FDA Approval For Senza II

* NEVRO RECEIVES FDA APPROVAL FOR SENZA II SPINAL CORD STIMULATION SYSTEM DELIVERING HF10 THERAPY Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Nevro Sees Q4 Revenue $97.4 Million To $97.9 Million

* NEVRO ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FISCAL YEAR 2017 REVENUE

08 Jan 2018

Earnings vs. Estimates